272 related articles for article (PubMed ID: 34463814)
1. Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO).
Shelan M; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Müller AC; Niehoff P; Pinkawa M; Schmidt-Hegemann NS; Sedlmayer F; Wolf F; Zamboglou C; Zips D; Wiegel T; Ghadjar P
Strahlenther Onkol; 2021 Nov; 197(11):993-1000. PubMed ID: 34463814
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care for prostate cancer radiotherapy-results from a survey among German-speaking radiation oncologists.
Vogel MME; Dewes S; Sage EK; Devecka M; Gschwend JE; Schiller K; Combs SE
Strahlenther Onkol; 2021 Nov; 197(11):962-970. PubMed ID: 33506347
[TBL] [Abstract][Full Text] [Related]
4. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO).
Rogowski P; Trapp C; von Bestenbostel R; Konnerth D; Marschner S; Schmidt Hegemann NS; Belka C; Li M
Strahlenther Onkol; 2022 Aug; 198(8):727-734. PubMed ID: 35364690
[TBL] [Abstract][Full Text] [Related]
7. Hypo- vs. normofractionated radiation therapy in breast cancer: A patterns of care analysis in German speaking countries.
Mayinger M; Straube C; Habermehl D; Duma MN; Combs SE
Rep Pract Oncol Radiother; 2020; 25(5):775-779. PubMed ID: 32904392
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated radiotherapy for localized prostate cancer.
Höcht S; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Hölscher T; Martin T; Sedlmayer F; Wenz F; Zips D; Wiegel T
Strahlenther Onkol; 2017 Jan; 193(1):1-12. PubMed ID: 27628966
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.
Morgan SC; Hoffman K; Loblaw DA; Buyyounouski MK; Patton C; Barocas D; Bentzen S; Chang M; Efstathiou J; Greany P; Halvorsen P; Koontz BF; Lawton C; Leyrer CM; Lin D; Ray M; Sandler H
Pract Radiat Oncol; 2018; 8(6):354-360. PubMed ID: 30322661
[TBL] [Abstract][Full Text] [Related]
10. Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.
Wolf F; Sedlmayer F; Aebersold D; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Ghadjar P; Höcht S; Hölscher T; Müller AC; Niehoff P; Pinkawa M; Schmidt-Hegemann NS; Zamboglou C; Zips D; Wiegel T
Strahlenther Onkol; 2021 Feb; 197(2):89-96. PubMed ID: 33301049
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil.
Palhares DMF; Pimentel LCF; Castilho MS; Costa ABD; Reisner ML; Kuhnen FQ; Pássaro A; Leite ETT; Faustino FLC; Obst FM; Costa FNBBF; Pioner GT; Carvalho ÍT; Silva JLFD; Morikawa LKK; Zanuncio PHDR; Hanriot RM; Rosa AA
Rev Assoc Med Bras (1992); 2021 Jan; 67(1):7-18. PubMed ID: 34161478
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionation Adoption in Prostate Cancer Radiotherapy: Results of an International Survey.
Sabbagh A; Weiss J; Tawk B; Mohammed MA; Abdulbaki H; Moraes FY; Grover S; Yap ML; Zubizarreta E; Lievens Y; Rodin D; Mohamad O
JCO Glob Oncol; 2023 Jun; 9():e2300046. PubMed ID: 37319396
[TBL] [Abstract][Full Text] [Related]
14. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature.
Francolini G; Detti B; Becherini C; Caini S; Ingrosso G; Di Cataldo V; Stocchi G; Salvestrini V; Lancia A; Scartoni D; Giacomelli I; Sardaro A; Carbonara R; Borghesi S; Aristei C; Livi L
Crit Rev Oncol Hematol; 2021 Sep; 165():103432. PubMed ID: 34352361
[TBL] [Abstract][Full Text] [Related]
15. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
[TBL] [Abstract][Full Text] [Related]
16. DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.
Souchon R; Sautter-Bihl ML; Sedlmayer F; Budach W; Dunst J; Feyer P; Fietkau R; Haase W; Harms W; Wenz F; Sauer R;
Strahlenther Onkol; 2014 Jan; 190(1):8-16. PubMed ID: 24306068
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
Morgan SC; Hoffman K; Loblaw DA; Buyyounouski MK; Patton C; Barocas D; Bentzen S; Chang M; Efstathiou J; Greany P; Halvorsen P; Koontz BF; Lawton C; Leyrer CM; Lin D; Ray M; Sandler H
J Urol; 2019 Mar; 201(3):528-534. PubMed ID: 30759696
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
